You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動|翰宇藥業升超5% HY3000已完成II期臨牀試驗
格隆匯 08-11 09:55
翰宇藥業升超5%,報11.6元,總市值102.5億元。公司昨日在互動平台上稱,針對HY3000對變異毒株包括EG.5.1的抑制效果,公司已安排開展假病毒實驗,事項進展情況公司將根據法律法規及時履行信息披露義務。根據此前完成的新冠病毒原型毒株及Omicron系列變異株亞型BA.3、BA.4/5、BA.1.1、BA.2.12.1、BA.2.13、BA.2.75、XBB、BQ.1、BQ.1.1、SRAS-COV、中東呼吸綜合徵病毒MERS-COV、以及冠狀流感等病毒的假毒抑制試驗,結果顯示HY3000具備冠狀病毒廣譜抑制性特點,截止目前已完成II期臨牀試驗,正進行數據清理和質量控制。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account